CD22L Conjugation to Insulin Attenuates Insulin-Specific B cell Activation
K. D. Apley, A. S. Griffith, G. Downes, P. A. Ross, M. P. Farrell, P. L. Kendall, C. J. Berkland
This paper develops insulin-CD22L conjugates to inhibit anti-insulin B cells in T1D, finding that low-valency conjugates reduce B cell activation while high-valency ones promote it.
bioRxiv · Jun 13, 2023Bioengineering